

Miscible with selenase®	Not miscible with selenase®
<ul style="list-style-type: none"> • 5% glucose solution • Ringer solution • Carbohydrate solutions (stability 72 hours (3 days)) • Colloidal volume expander solutions (stability 72 hours (3 days)) • Electrolyte solutions with increased potassium concentration (stability 48 hours (2 days)) • Crystalloid electrolyte solutions (stability 48 hours (2 days)) • Amino acid solutions without cysteine (stability 36 hours (1.5 days)) • Fat emulsions (stability 24 hours (1 day)) • Vitamin solutions (without vitamin C) 	<ul style="list-style-type: none"> • Cytostatic agent solutions^[1] • Amino acid solutions that contain cysteine^[2] • Solutions that contain glutathione (GSH)^[3] • Vitamin solutions that contain vitamin C^[4] <p>[1] selenase® should generally be administered 1 hour before cytostatic agent application for timely incorporation in the endogenous protective systems.</p> <p>[2, 3] SH groups react with Na-selenite; Na-selenite can no longer act as a radical scavenger.</p> <p>[4] Selenium (Se^{+IV}) in sodium selenite is reduced by vitamin C to the elementary selenium (Se⁰) and is thereby ineffective.</p>

Robinson MF, Thomson CD, Huemmer PK. N Z Med J. 1985 Aug 14; 98(784): 627-9. [Effect of a megadose of ascorbic acid, a meal and orange juice on the absorption of selenium as sodium selenite.](#)

Ip C. J Natl Cancer Inst. 1986 Jul; 77(1): 299-303. [Interaction of vitamin C and selenium supplementation in the modification of mammary carcinogenesis in rats.](#)

Volumes

Bolus (within 6 hours)	2,000 µg selenium (40 ml selenase® T pro injectione) in 100 ml saline within one hour ^[1]
Continuous infusion (at least 7 days)	1,500 µg selenium (30 ml selenase® T pro injectione) in 250 ml saline during 12 hours for 14 days ^[1]

[1] Chelkeba L, et al. Ann Intensive Care. 2015 Dec; 5(1): 29. [The effect of parenteral selenium on outcomes of mechanically ventilated patients following sepsis: a prospective randomized clinical trial.](#)

Products for injection therapy

Prescription only

selenase® 100 µg
pro injektionen

100 µg selenium/injection ampoule



10 (N2) and 50 ampoules with 2 ml solution
for injection

selenase® T
pro injektionen

500 µg selenium/injection vials



2, 10 (N2), 30 (3 × 10) and 50 (5 × 10) glass vials
with 10 ml solution for injection

selenase® corrects selenium deficiency

selenase® 100 µg/T pro injektionen: **Active substance:** Sodium selenite pentahydrate, 50 µg selenium per ml. **Indications:** Proven selenium deficiency that cannot be offset from food sources. Selenium deficiencies may occur as a result of states of maldigestion and malabsorption, as well as in malnutrition (e.g. due to complete parenteral nutrition). **Composition:** **selenase® 100 µg pro injektionen:** 1 ampoule of 2 ml solution for injection contains: 0.333 mg sodium selenite pentahydrate, corresponding to 100 µg (micrograms) selenium. **selenase® T pro injektionen:** 1 injection vial of 10 ml/20 ml solution for injection contains: 1.67 mg/3.33 mg sodium selenite pentahydrate, corresponding to 500 µg/1000 µg (micrograms) selenium. **Excipients:** Sodium chloride, hydrochloric acid, water for injections. **Contra-**

indications: Selenium poisoning. **Undesirable effects:** *General disorders and administration site conditions:* Frequency not known (cannot be estimated from the available data): after intramuscular administration local pain at the site of administration has been reported. **Form of administration, size of packages:** **selenase® 100 µg pro injektionen:** 10 or 50 ampoules of 2 ml solution for injection. **selenase® T pro injektionen:** 2 or 10 injection vials of 10 ml solution for injection, hospital-size pack 30 (3 × 10) or 50 (5 × 10) injection vials of 10 ml solution for injection, 2 or 10 injection vials of 20 ml solution for injection, hospital-size pack 30 (3 × 10) or 50 (5 × 10) injection vials of 20 ml solution for injection. Subject to prescription 01/17e

Additional information

Brochures

We would be glad to send you our detailed brochure “Selenium in intensive care as adjunctive therapy for sepsis, ischaemia/reperfusion and reanimation”.

Order by email: information@biosyn.de
(key word “Intensive care brochure”).

Moreover, we offer extensive information on the topics “Selenium in oncology” and “Selenium and the thyroid gland” – for health professionals and patients.

Website

Please find further information on our website
www.biosynpharma.com